268 related articles for article (PubMed ID: 28414304)
1. Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia.
Sumner ET; Chawla AT; Cororaton AD; Koblinski JE; Kovi RC; Love IM; Szomju BB; Korwar S; Ellis KC; Grossman SR
Oncogene; 2017 Aug; 36(33):4810-4816. PubMed ID: 28414304
[TBL] [Abstract][Full Text] [Related]
2. Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.
Dcona MM; Damle PK; Zarate-Perez F; Morris BL; Nawaz Z; Dennis MJ; Deng X; Korwar S; Singh SJ; Ellis KC; Royer WE; Bandyopadhyay D; Escalante C; Grossman SR
Mol Pharmacol; 2019 Jul; 96(1):99-108. PubMed ID: 31036695
[TBL] [Abstract][Full Text] [Related]
3. APC mutations in colorectal tumours from FAP patients are selected for CtBP-mediated oligomerization of truncated APC.
Schneikert J; Brauburger K; Behrens J
Hum Mol Genet; 2011 Sep; 20(18):3554-64. PubMed ID: 21665989
[TBL] [Abstract][Full Text] [Related]
4. The APC tumor suppressor binds to C-terminal binding protein to divert nuclear beta-catenin from TCF.
Hamada F; Bienz M
Dev Cell; 2004 Nov; 7(5):677-85. PubMed ID: 15525529
[TBL] [Abstract][Full Text] [Related]
5. Adenomatous polyposis coli control of C-terminal binding protein-1 stability regulates expression of intestinal retinol dehydrogenases.
Nadauld LD; Phelps R; Moore BC; Eisinger A; Sandoval IT; Chidester S; Peterson PW; Manos EJ; Sklow B; Burt RW; Jones DA
J Biol Chem; 2006 Dec; 281(49):37828-35. PubMed ID: 17028196
[TBL] [Abstract][Full Text] [Related]
6. An intestinal stem cell niche in
Chawla AT; Cororaton AD; Idowu MO; Damle PK; Szomju B; Ellis KC; Patel BB; Grossman SR
Oncotarget; 2018 Aug; 9(65):32408-32418. PubMed ID: 30197752
[TBL] [Abstract][Full Text] [Related]
7. A two-step model for colon adenoma initiation and progression caused by APC loss.
Phelps RA; Chidester S; Dehghanizadeh S; Phelps J; Sandoval IT; Rai K; Broadbent T; Sarkar S; Burt RW; Jones DA
Cell; 2009 May; 137(4):623-34. PubMed ID: 19450512
[TBL] [Abstract][Full Text] [Related]
8. A targeted constitutive mutation in the APC tumor suppressor gene underlies mammary but not intestinal tumorigenesis.
Gaspar C; Franken P; Molenaar L; Breukel C; van der Valk M; Smits R; Fodde R
PLoS Genet; 2009 Jul; 5(7):e1000547. PubMed ID: 19578404
[TBL] [Abstract][Full Text] [Related]
9. Adenomatous polyposis coli (APC) membrane recruitment 3, a member of the APC membrane recruitment family of APC-binding proteins, is a positive regulator of Wnt-β-catenin signalling.
Brauburger K; Akyildiz S; Ruppert JG; Graeb M; Bernkopf DB; Hadjihannas MV; Behrens J
FEBS J; 2014 Feb; 281(3):787-801. PubMed ID: 24251807
[TBL] [Abstract][Full Text] [Related]
10. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.
Birts CN; Harding R; Soosaipillai G; Halder T; Azim-Araghi A; Darley M; Cutress RI; Bateman AC; Blaydes JP
Biol Cell; 2010 Jan; 103(1):1-19. PubMed ID: 20964627
[TBL] [Abstract][Full Text] [Related]
11. Functional comparison of human adenomatous polyposis coli (APC) and APC-like in targeting beta-catenin for degradation.
Schneikert J; Vijaya Chandra SH; Ruppert JG; Ray S; Wenzel EM; Behrens J
PLoS One; 2013; 8(7):e68072. PubMed ID: 23840886
[TBL] [Abstract][Full Text] [Related]
12. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells.
Yang J; Zhang W; Evans PM; Chen X; He X; Liu C
J Biol Chem; 2006 Jun; 281(26):17751-7. PubMed ID: 16798748
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of C-terminal binding protein attenuates transcription factor 4 signaling to selectively target colon cancer stem cells.
Patel J; Baranwal S; Love IM; Patel NJ; Grossman SR; Patel BB
Cell Cycle; 2014; 13(22):3506-18. PubMed ID: 25483087
[TBL] [Abstract][Full Text] [Related]
14. Ovarian steroid cell tumor with biallelic adenomatous polyposis coli inactivation in a patient with familial adenomatous polyposis.
Hu PJ; Knoepp SM; Wu R; Cho KR
Genes Chromosomes Cancer; 2012 Mar; 51(3):283-9. PubMed ID: 22120905
[TBL] [Abstract][Full Text] [Related]
15. Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis.
Ghaleb AM; McConnell BB; Nandan MO; Katz JP; Kaestner KH; Yang VW
Cancer Res; 2007 Aug; 67(15):7147-54. PubMed ID: 17671182
[TBL] [Abstract][Full Text] [Related]
16. Targeted suppression of beta-catenin blocks intestinal adenoma formation in APC Min mice.
Foley PJ; Scheri RP; Smolock CJ; Pippin J; Green DW; Drebin JA
J Gastrointest Surg; 2008 Aug; 12(8):1452-8. PubMed ID: 18521697
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model.
Hardiman KM; Liu J; Feng Y; Greenson JK; Fearon ER
PLoS One; 2014; 9(4):e96023. PubMed ID: 24763434
[TBL] [Abstract][Full Text] [Related]
18. Suppression of intestinal tumorigenesis in
Wolfe AR; Ernlund A; McGuinness W; Lehmann C; Carl K; Balmaceda N; Neufeld KL
J Cell Sci; 2017 Feb; 130(4):805-813. PubMed ID: 28082422
[TBL] [Abstract][Full Text] [Related]
19. Contribution of the 15 amino acid repeats of truncated APC to beta-catenin degradation and selection of APC mutations in colorectal tumours from FAP patients.
Kohler EM; Brauburger K; Behrens J; Schneikert J
Oncogene; 2010 Mar; 29(11):1663-71. PubMed ID: 19966865
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of intestinal polyposis with reduced angiogenesis in ApcMin/+ mice due to decreases in c-Myc expression.
Yekkala K; Baudino TA
Mol Cancer Res; 2007 Dec; 5(12):1296-303. PubMed ID: 18171987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
